Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Regenerx Biopharmaceuticals, Inc. (RGRX) Starts Presentation at LD Micro Conference

Regenerx Biopharmaceuticals currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, and three active strategic licensing agreements in China, Pan Asia and in the U.S. RGN-259, the company’s TB-based ophthalmic drug candidate is being developed for dry eye syndrome and for the treatment of neurotrophic keratopathy (NK).  RGN-259 has been granted orphan status by the U.S. FDA and was recently allowed by the FDA to move into phase 3 clinical trials for the treatment of patients with NK.  RGN-352 is its phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar injuries. RGN-137 is in phase 2 clinical development. For more information, visit the company’s website at

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.